The DOI matches its Crossref record; 386 of the 386 references it cites were found in a registry or an index.
Chemistry, structure and function of approved oligonucleotide therapeutics
Open accessAbstract
Eighteen nucleic acid therapeutics have been approved for treatment of various diseases in the last 25 years. Their modes of action include antisense oligonucleotides (ASOs), splice-switching oligonucleotides (SSOs), RNA interference (RNAi) and an RNA aptamer against a protein. Among the diseases targeted by this new class of drugs are homozygous familial hypercholesterolemia, spinal muscular atrophy, Duchenne muscular dystrophy, hereditary transthyretin-mediated amyloidosis, familial chylomicronemia syndrome, acute hepatic porphyria, and primary hyperoxaluria. Chemical modification of DNA and RNA was central to making drugs out of oligonucleotides. Oligonucleotide therapeutics brought to market thus far contain just a handful of first- and second-generation modifications, among them 2′-fluoro-RNA, 2′-O-methyl RNA and the phosphorothioates that were introduced over 50 years ago. Two other privileged chemistries are 2′-O-(2-methoxyethyl)-RNA (MOE) and the phosphorodiamidate morpholinos (PMO). Given their importance in imparting oligonucleotides with high target affinity, metabolic stability and favorable pharmacokinetic and -dynamic properties, this article provides a review of these chemistries and their use in nucleic acid therapeutics. Breakthroughs in lipid formulation and GalNAc conjugation of modified oligonucleotides have paved the way to efficient delivery and robust, long-lasting silencing of genes. This review provides an account of the state-of-the-art of targeted oligo delivery to hepatocytes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,828
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid
WATSON, J. D., & CRICK, F. H. C. (1953) · Nature · doi:10.1038/171737a0 · Cited by 13,584
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
The Amber biomolecular simulation programs
Case, D. A., Cheatham, T. E., Darden, T., Gohlke, H., Luo, R., Merz, K. M., Onufriev, A., Simmerling, C., Wang, B., & Woods, R. J. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20290 · Cited by 9,535
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
On computable numbers, with an application to the entscheidungsproblem
Turing, A. M. (1937) · Proceedings of the London Mathematical Society · doi:10.1112/plms/s2-42.1.230 · Cited by 8,283
Lead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199
Role for a bidentate ribonuclease in the initiation step of RNA interference
Bernstein, E., Caudy, A. A., Hammond, S. M., & Hannon, G. J. (2001) · Nature · doi:10.1038/35053110 · Cited by 4,892
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Mammen, M., Choi, S.-K., & Whitesides, G. M. (1998) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19981102)37:20<2754::aid-anie2754>3.0.co;2-3 · Cited by 4,110
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
The Many Roles for Fluorine in Medicinal Chemistry
Hagmann, W. K. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800219f · Cited by 3,578
CpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406 · cited 1×
“As well a preliminary account of a phase 1, dose-escalation, open-label trial with mRNA-1273 that included 45 healthy adults reported vaccine-induced anti-SARS-CoV-2 immune responses in all participants and an absence of trial-limiting safety concerns (419).”
BackgroundDoherty, G. J., & McMahon, H. T. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.081307.110540 · Cited by 3,075
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Foreman, K. J., Marquez, N., Dolgert, A., Fukutaki, K., Fullman, N., McGaughey, M., Pletcher, M. A., Smith, A. E., Tang, K., Yuan, C.-W., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31694-5 · Cited by 2,994
Argonaute2 is the catalytic engine of mammalian RNAi
Liu, J., Carmell, M. A., Rivas, F. V., Marsden, C. G., Thomson, J. M., Song, J.-J., Hammond, S. M., Joshua-Tor, L., & Hannon, G. J. (2004) · Science · doi:10.1126/science.1102513 · Cited by 2,796
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Self-citationAltona, C., & Sundaralingam, M. (1972) · Journal of the American Chemical Society · doi:10.1021/ja00778a043 · Cited by 2,056
Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs
Meister, G., Landthaler, M., Patkaniowska, A., Dorsett, Y., Teng, G., & Tuschl, T. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.07.007 · Cited by 2,052
Advances in oligonucleotide drug delivery
Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,027
Deoxynucleoside phosphoramidites—A new class of key intermediates for deoxypolynucleotide synthesis
Beaucage, S. L., & Caruthers, M. H. (1981) · Tetrahedron Letters · doi:10.1016/s0040-4039(01)90461-7 · Cited by 1,993
Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792
MODOMICS: a database of RNA modification pathways. 2017 update
Boccaletto, P., Machnicka, M. A., Purta, E., Piątkowski, P., Bagiński, B., Wirecki, T. K., de Crécy-Lagard, V., Ross, R., Limbach, P. A., Kotter, A., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1030 · Cited by 1,782
A vision for the future of genomics research
Collins, F. S., Green, E. D., Guttmacher, A. E., Guyer, M. S., & on behalf of the US National Human Genome Research Institute (2003) · Nature · doi:10.1038/nature01626 · Cited by 1,752
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912387 · Cited by 1,665
Antisense oligonucleotides: a new therapeutic principle
Uhlmann, E., & Peyman, A. (1990) · Chemical Reviews · doi:10.1021/cr00102a001 · Cited by 1,640
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Self-citationPegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
Endosomal escape pathways for delivery of biologicals
Varkouhi, A. K., Scholte, M., Storm, G., & Haisma, H. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.004 · Cited by 1,561
Crystal Structure of Argonaute and Its Implications for RISC Slicer Activity
Song, J.-J., Smith, S. K., Hannon, G. J., & Joshua-Tor, L. (2004) · Science · doi:10.1126/science.1102514 · Cited by 1,470
The current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357 · cited 1×
“in mice (340) and systemic delivery in a liposomal formulation to non-human primates (341).”
BackgroundTherapeutic potential of Toll-like receptor 9 activation
Krieg, A. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2059 · Cited by 1,246
Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141
Self-citationMorpholino Antisense Oligomers: Design, Preparation, and Properties
SUMMERTON, J., & WELLER, D. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.187 · Cited by 1,116
RNAi therapeutics: a potential new class of pharmaceutical drugs
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,085
Self-citationMolecular Mechanisms of RNA Interference
Wilson, R. C., & Doudna, J. A. (2013) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-083012-130404 · Cited by 1,076
Koshkin, A. A., Singh, S. K., Nielsen, P., Rajwanshi, V. K., Kumar, R., Meldgaard, M., Olsen, C. E., & Wengel, J. (1998) · Tetrahedron · doi:10.1016/s0040-4020(98)00094-5 · Cited by 1,047
Caplen, N. J., Parrish, S., Imani, F., Fire, A., & Morgan, R. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171251798 · Cited by 1,043
Base-stacking and base-pairing contributions into thermal stability of the DNA double helix
Yakovchuk, P. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj454 · Cited by 997
Lunn, M. R., & Wang, C. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60921-6 · Cited by 995
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs
Wolfrum, C., Shi, S., Jayaprakash, K. N., Jayaraman, M., Wang, G., Pandey, R. K., Rajeev, K. G., Nakayama, T., Charrise, K., Ndungo, E. M., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1339 · Cited by 974
Self-citationSequence- and target-independent angiogenesis suppression by siRNA via TLR3
Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J. Z., Albuquerque, R. J. C., Yamasaki, S., Itaya, M., Pan, Y., et al. (2008) · Nature · doi:10.1038/nature06765 · Cited by 929
Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.
Stephenson, M. L., & Zamecnik, P. C. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.285 · Cited by 906
Origins of Specificity in Protein-DNA Recognition
Rohs, R., Jin, X., West, S. M., Joshi, R., Honig, B., & Mann, R. S. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060408-091030 · Cited by 896
Synthesis of deoxyoligonucleotides on a polymer support
Matteucci, M. D., & Caruthers, M. H. (1981) · Journal of the American Chemical Society · doi:10.1021/ja00401a041 · Cited by 889
The delivery of therapeutic oligonucleotides
Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 854
Eckstein, F. (1985) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.54.070185.002055 · Cited by 849
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913805 · Cited by 818
Sanger, F., & Tuppy, H. (1951) · Biochemical Journal · doi:10.1042/bj0490463 · Cited by 784
Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L., & Janjic, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 744
Synthetic genetic polymers capable of heredity and evolution
Pinheiro, V. B., Taylor, A. I., Cozens, C., Abramov, M., Renders, M., Zhang, S., Chaput, J. C., Wengel, J., Peak-Chew, S.-Y., McLaughlin, S. H., et al. (2012) · Science · doi:10.1126/science.1217622 · Cited by 730
Freier, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.22.4429 · Cited by 692
Structural basis for 5′-nucleotide base-specific recognition of guide RNA by human AGO2
Frank, F., Sonenberg, N., & Nagar, B. (2010) · Nature · doi:10.1038/nature09039 · Cited by 666
Advances in mRNA Vaccines for Infectious Diseases
Zhang, C., Maruggi, G., Shan, H., & Li, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00594 · Cited by 665
Recent Advances in Aptamer Discovery and Applications
Zhang, Y., Lai, B. S., & Juhas, M. (2019) · Molecules · doi:10.3390/molecules24050941 · Cited by 663
Structural basis for 5′-end-specific recognition of guide RNA by the A. fulgidus Piwi protein
Ma, J.-B., Yuan, Y.-R., Meister, G., Pei, Y., Tuschl, T., & Patel, D. J. (2005) · Nature · doi:10.1038/nature03514 · Cited by 657
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
Developing mRNA-vaccine technologies
Schlake, T., Thess, A., Fotin-Mleczek, M., & Kallen, K.-J. (2012) · RNA Biology · doi:10.4161/rna.22269 · Cited by 622
Asialoglycoprotein receptor mediated hepatocyte targeting — Strategies and applications
D'Souza, A. A., & Devarajan, P. V. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.022 · Cited by 621
Nowotny, M., Gaidamakov, S. A., Crouch, R. J., & Yang, W. (2005) · Cell · doi:10.1016/j.cell.2005.04.024 · Cited by 620 · cited 3×
“An overlay of crystal structures of Bacillus halodurans RNase H bound to an RNA-DNA substrate duplex (162) and a DNA–DNA inhibitor duplex of the same length (218) shows that the groove widths and strand curvatures in the two duplexes differ distinctly (Figure 8C).”
BackgroundThe Structure of Human Argonaute-2 in Complex with miR-20a
Elkayam, E., Kuhn, C.-D., Tocilj, A., Haase, A. D., Greene, E. M., Hannon, G. J., & Joshua-Tor, L. (2012) · Cell · doi:10.1016/j.cell.2012.05.017 · Cited by 613
Obika, S., Nanbu, D., Hari, Y., Morio, K.-I., In, Y., Ishida, T., & Imanishi, T. (1997) · Tetrahedron Letters · doi:10.1016/s0040-4039(97)10322-7 · Cited by 610
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
Balwani, M., Sardh, E., Ventura, P., Peiró, P. A., Rees, D. C., Stölzel, U., Bissell, D. M., Bonkovsky, H. L., Windyga, J., Anderson, K. E., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913147 · Cited by 608
Nimjee, S. M., White, R. R., Becker, R. C., & Sullenger, B. A. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104558 · Cited by 607
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids
Hafez, I., Maurer, N., & Cullis, P. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301506 · Cited by 601
Physicochemical properties of phospborothioate oligodeoxynucleotides
Stein, C. A., Subasinghe, C., Shinozuka, K., & Cohen, J. S. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.8.3209 · Cited by 591
Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing
Deleavey, G. F., & Damha, M. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.07.011 · Cited by 589
Cellular uptake and trafficking of antisense oligonucleotides
Crooke, S. T., Wang, S., Vickers, T. A., Shen, W., & Liang, X.-H. (2017) · Nature Biotechnology · doi:10.1038/nbt.3779 · Cited by 582
Origins and evolution of viruses of eukaryotes: The ultimate modularity
Koonin, E. V., Dolja, V. V., & Krupovic, M. (2015) · Virology · doi:10.1016/j.virol.2015.02.039 · Cited by 570
Sanger, F., & Thompson, E. O. P. (1953) · Biochemical Journal · doi:10.1042/bj0530353 · Cited by 567 · cited 1×
“Consider what has been achieved in roughly that time frame as we went from: the Wright brothers’ first flight (1903) (1) to manned space flight (Gagarin/Sheppard, 1961) (2), Turing’s paper on computable numbers and the decision problem (Turing machine, 1936) (3,4) to the release of the Cray-2 supercomputer (1985) (5),…”
BackgroundStructural basis for microRNA targeting
Schirle, N. T., Sheu-Gruttadauria, J., & MacRae, I. J. (2014) · Science · doi:10.1126/science.1258040 · Cited by 562
Origins and evolution of eukaryotic RNA interference
SHABALINA, S., & KOONIN, E. (2008) · Trends in Ecology & Evolution · doi:10.1016/j.tree.2008.06.005 · Cited by 561
Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy
Sun, H., Zhu, X., Lu, P. Y., Rosato, R. R., Tan, W., & Zu, Y. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.32 · Cited by 541
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
Garrelfs, S. F., Frishberg, Y., Hulton, S. A., Koren, M. J., O’Riordan, W. D., Cochat, P., Deschênes, G., Shasha-Lavsky, H., Saland, J. M., van’t Hoff, W. G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021712 · Cited by 531
Structural insights into mRNA recognition from a PIWI domain–siRNA guide complex
Parker, J. S., Roe, S. M., & Barford, D. (2005) · Nature · doi:10.1038/nature03462 · Cited by 530
McBride, L. J., & Caruthers, M. H. (1983) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)81376-3 · Cited by 516
The evolution of RNAi as a defence against viruses and transposable elements
Obbard, D. J., Gordon, K. H. J., Buck, A. H., & Jiggins, F. M. (2009) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2008.0168 · Cited by 516
Generation of high-affinity DNA aptamers using an expanded genetic alphabet
Kimoto, M., Yamashige, R., Matsunaga, K.-I., Yokoyama, S., & Hirao, I. (2013) · Nature Biotechnology · doi:10.1038/nbt.2556 · Cited by 510
Seiler, M., Yoshimi, A., Darman, R., Chan, B., Keaney, G., Thomas, M., Agrawal, A. A., Caleb, B., Csibi, A., Sean, E., et al. (2018) · Nature Medicine · doi:10.1038/nm.4493 · Cited by 507
Sanger, F., & Tuppy, H. (1951) · Biochemical Journal · doi:10.1042/bj0490481 · Cited by 505
Eteplirsen in the treatment of Duchenne muscular dystrophy
Lim, K. R., Maruyama, R., & Yokota, T. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s97635 · Cited by 495
Insights into RNA structure and function from genome-wide studies
Mortimer, S. A., Kidwell, M. A., & Doudna, J. A. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3681 · Cited by 472
Swayze, E. E., Siwkowski, A. M., Wancewicz, E. V., Migawa, M. T., Wyrzykiewicz, T. K., Hung, G., Monia, B. P., & Bennett, A. C. F. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl1071 · Cited by 469
Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines
Nance, K. D., & Meier, J. L. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00197 · Cited by 466
DNA conformation is determined by economics in the hydration of phosphate groups
Saenger, W., Hunter, W. N., & Kennard, O. (1986) · Nature · doi:10.1038/324385a0 · Cited by 448
Allerson, C. R., Sioufi, N., Jarres, R., Prakash, T. P., Naik, N., Berdeja, A., Wanders, L., Griffey, R. H., Swayze, E. E., & Bhat, B. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049167j · Cited by 448
Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease
Adams, D., Koike, H., Slama, M., & Coelho, T. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0210-4 · Cited by 448
Monia, B. P., Johnston, J. F., Geiger, T., Muller, M., & Fabbro, D. (1996) · Nature Medicine · doi:10.1038/nm0696-668 · Cited by 447
Natural history of HIV infection in the_era of combination antiretroviral therapy
Moore, R. D., & Chaisson, R. E. (1999) · AIDS · doi:10.1097/00002030-199910010-00017 · Cited by 443
Kawasaki, A. M., Casper, M. D., Freier, S. M., Lesnik, E. A., Zounes, M. C., Cummins, L. L., Gonzalez, C., & Cook, P. D. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00059a007 · Cited by 438
Levin, A. A. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00140-2 · Cited by 438
Dunitz, J. D. (2004) · ChemBioChem · doi:10.1002/cbic.200300801 · Cited by 423
Scott, L. J. (2020) · Drugs · doi:10.1007/s40265-020-01269-0 · Cited by 420
Progress in antisense technology
Crooke, S. T. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104408 · Cited by 417
Recent developments in age-related macular degeneration: a review
Al-Zamil, W., & Yassin, S. (2017) · Clinical Interventions in Aging · doi:10.2147/cia.s143508 · Cited by 406
On the role of helper lipids in lipid nanoparticle formulations of siRNA
Kulkarni, J. A., Witzigmann, D., Leung, J., Tam, Y. Y. C., & Cullis, P. R. (2019) · Nanoscale · doi:10.1039/c9nr09347h · Cited by 402
Molecular Mechanisms of Antisense Oligonucleotides
Crooke, S. T. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0656 · Cited by 396
Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
Hammond, S. M., Aartsma‐Rus, A., Alves, S., Borgos, S. E., Buijsen, R. A. M., Collin, R. W. J., Covello, G., Denti, M. A., Desviat, L. R., Echevarría, L., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013243 · Cited by 388
Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9
Ohto, U., Shibata, T., Tanji, H., Ishida, H., Krayukhina, E., Uchiyama, S., Miyake, K., & Shimizu, T. (2015) · Nature · doi:10.1038/nature14138 · Cited by 377
Iwamoto, N., Butler, D. C. D., Svrzikapa, N., Mohapatra, S., Zlatev, I., Sah, D. W. Y., Meena, Standley, S. M., Lu, G., Apponi, L. H., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3948 · Cited by 377
Soyfer, V. N., & Potaman, V. N. (1996) · Springer eBooks · doi:10.1007/978-1-4612-3972-7 · Cited by 361
Lamb, Y. N. (2021) · Drugs · doi:10.1007/s40265-021-01473-6 · Cited by 359
Activation of the mammalian immune system by siRNAs
Marques, J. T., & Williams, B. R. G. (2005) · Nature Biotechnology · doi:10.1038/nbt1161 · Cited by 358
Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history
FITZGERALDBOCARSLY, P., DAI, J., & SINGH, S. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.10.006 · Cited by 351
Manoharan, M. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00138-4 · Cited by 348
Self-citationDirect In Vitro Selection of a 2′-O-Methyl Aptamer to VEGF
Burmeister, P. E., Lewis, S. D., Silva, R. F., Preiss, J. R., Horwitz, L. R., Pendergrast, P. S., McCauley, T. G., Kurz, J. C., Epstein, D. M., Wilson, C., et al. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.10.017 · Cited by 347
RNA interference and chemically modified small interfering RNAs
Manoharan, M. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.10.007 · Cited by 346
Self-citationEffect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding.
Brown, D. A., Kang, S. H., Gryaznov, S. M., DeDionisio, L., Heidenreich, O., Sullivan, S., Xu, X., & Nerenberg, M. I. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47090-1 · Cited by 336
Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates
Foster, D. J., Brown, C. R., Shaikh, S., Trapp, C., Schlegel, M. K., Qian, K., Sehgal, A., Rajeev, K. G., Jadhav, V., Manoharan, M., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.021 · Cited by 325
Self-citationTherapeutic Oligonucleotides: State of the Art
Smith, C. I. E., & Zain, R. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021050 · Cited by 323
Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes
Ni, S., Yao, H., Wang, L., Lu, J., Jiang, F., Lu, A., & Zhang, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081683 · Cited by 321
Heo, Y.-A. (2020) · Drugs · doi:10.1007/s40265-020-01267-2 · Cited by 317
Structure of Human RNase H1 Complexed with an RNA/DNA Hybrid: Insight into HIV Reverse Transcription
Nowotny, M., Gaidamakov, S. A., Ghirlando, R., Cerritelli, S. M., Crouch, R. J., & Yang, W. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.08.015 · Cited by 316
Bacterial CpG DNA Activates Immune Cells to Signal Infectious Danger
Wagner, H. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60790-7 · Cited by 314
Crystal structure of a junction between B-DNA and Z-DNA reveals two extruded bases
Ha, S. C., Lowenhaupt, K., Rich, A., Kim, Y.-G., & Kim, K. K. (2005) · Nature · doi:10.1038/nature04088 · Cited by 309
COVID-19 mRNA vaccines: Platforms and current developments
Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308
Letsinger, R. L., Zhang, G. R., Sun, D. K., Ikeuchi, T., & Sarin, P. S. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.17.6553 · Cited by 304
Unlocking P(V): Reagents for chiral phosphorothioate synthesis
Knouse, K. W., deGruyter, J. N., Schmidt, M. A., Zheng, B., Vantourout, J. C., Kingston, C., Mercer, S. E., Mcdonald, I. M., Olson, R. E., Zhu, Y., et al. (2018) · Science · doi:10.1126/science.aau3369 · Cited by 303
Scott, L. J., & Keam, S. J. (2021) · Drugs · doi:10.1007/s40265-020-01463-0 · Cited by 292
Pharmacokinetic Properties of 2′-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats
Geary, R. S., Watanabe, T. A., Truong, L., Freier, S., Lesnik, E. A., Sioufi, N. B., Sasmor, H., Manoharan, M., & Levin, A. A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38831-7 · Cited by 288
Self-citationSynthesis of thymidine oligonucleotides by phosphite triester intermediates
Letsinger, R. L., & Lunsford, W. B. (1976) · Journal of the American Chemical Society · doi:10.1021/ja00428a045 · Cited by 283
Campbell, M. A., & Wengel, J. (2011) · Chemical Society Reviews · doi:10.1039/c1cs15048k · Cited by 279
Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity
Janas, M. M., Schlegel, M. K., Harbison, C. E., Yilmaz, V. O., Jiang, Y., Parmar, R., Zlatev, I., Castoreno, A., Xu, H., Shulga-Morskaya, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02989-4 · Cited by 279
Self-citationNair, J. K., Attarwala, H., Sehgal, A., Wang, Q., Aluri, K., Zhang, X., Gao, M., Liu, J., Indrakanti, R., Schofield, S., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx818 · Cited by 278
Self-citationStec, W. J., Zon, G., & Egan, W. (1984) · Journal of the American Chemical Society · doi:10.1021/ja00332a054 · Cited by 276
Phosphorothioation of DNA in bacteria by dnd genes
Wang, L., Chen, S., Xu, T., Taghizadeh, K., Wishnok, J. S., Zhou, X., You, D., Deng, Z., & Dedon, P. C. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.39 · Cited by 274
Total Synthesis of the Gene for an Alanine Transfer Ribonucleic Acid from Yeast
AGARWAL, K. L., BÜCHI, H., CARUTHERS, M. H., GUPTA, N., KHORANA, H. G., KLEPPE, K., KUMAR, A., OHTSUKA, E., RAJBHANDARY, U. L., VAN DE SANDE, J. H., et al. (1970) · Nature · doi:10.1038/227027a0 · Cited by 274
Shirley, M. (2021) · Drugs · doi:10.1007/s40265-021-01512-2 · Cited by 274
The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines
Morais, P., Adachi, H., & Yu, Y.-T. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.789427 · Cited by 273
Rader, D. J., & Kastelein, J. J. P. (2014) · Circulation · doi:10.1161/circulationaha.113.001292 · Cited by 264
Sanger, F., & Thompson, E. O. P. (1953) · Biochemical Journal · doi:10.1042/bj0530366 · Cited by 260 · cited 1×
“Consider what has been achieved in roughly that time frame as we went from: the Wright brothers’ first flight (1903) (1) to manned space flight (Gagarin/Sheppard, 1961) (2), Turing’s paper on computable numbers and the decision problem (Turing machine, 1936) (3,4) to the release of the Cray-2 supercomputer (1985) (5),…”
BackgroundExpanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates
Brown, K. M., Nair, J. K., Janas, M. M., Anglero-Rodriguez, Y. I., Dang, L. T. H., Peng, H., Theile, C. S., Castellanos-Rizaldos, E., Brown, C., Foster, D., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01334-x · Cited by 258 · cited 1×
“A lipid-conjugated siRNA for CNS applications (429) and an antibody-conjugated siRNA for muscle delivery (430) have entered clinical studies.”
BackgroundSelf-citationSingle-Stranded siRNAs Activate RNAi in Animals
Lima, W. F., Prakash, T. P., Murray, H. M., Kinberger, G. A., Li, W., Chappell, A. E., Li, C. S., Murray, S. F., Gaus, H., Seth, P. P., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.014 · Cited by 256
Kim, S. C., Sekhon, S. S., Shin, W.-R., Ahn, G., Cho, B.-K., Ahn, J.-Y., & Kim, Y.-H. (2022) · Molecular & Cellular Toxicology · doi:10.1007/s13273-021-00171-4 · Cited by 255
Structure of a DNA : RNA Hybrid Duplex
Fedoroff, O. Y., Salazar, M., & Reid, B. R. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1528 · Cited by 247
Perry, C. M., & Barman Balfour, J. A. (1999) · Drugs · doi:10.2165/00003495-199957030-00010 · Cited by 243
Lee, J.-H., Canny, M. D., De Erkenez, A., Krilleke, D., Ng, Y.-S., Shima, D. T., Pardi, A., & Jucker, F. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509069102 · Cited by 242
Antisense Oligonucleotides: Promise and Reality
Lebedeva, I., & Stein, C. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.403 · Cited by 236
Ein neuer Zugang zu 2′‐O‐Alkylribonucleosiden und Eigenschaften deren Oligonucleotide
Martin, P. (1995) · Helvetica Chimica Acta · doi:10.1002/hlca.19950780219 · Cited by 234
DNA Nanostructures at the Interface with Biology
Bujold, K. E., Lacroix, A., & Sleiman, H. F. (2018) · Chem · doi:10.1016/j.chempr.2018.02.005 · Cited by 231
Bioconjugated Oligonucleotides: Recent Developments and Therapeutic Applications
Benizri, S., Gissot, A., Martin, A., Vialet, B., Grinstaff, M. W., & Barthélémy, P. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00761 · Cited by 231
The safety of Covid-19 mRNA vaccines: a review
Anand, P., & Stahel, V. P. (2021) · Patient Safety in Surgery · doi:10.1186/s13037-021-00291-9 · Cited by 230
An RNA toolbox for cancer immunotherapy
Pastor, F., Berraondo, P., Etxeberria, I., Frederick, J., Sahin, U., Gilboa, E., & Melero, I. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.132 · Cited by 229
A NEW TWO STRANDED HELICAL STRUCTURE: POLYADENYLIC ACID AND POLYURIDYLIC ACID
Rich, A., & Davies, D. R. (1956) · Journal of the American Chemical Society · doi:10.1021/ja01595a086 · Cited by 226
Synthetic metallonucleases for RNA cleavage
Morrow, J. R., & Iranzo, O. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.02.006 · Cited by 224
Matsuda, S., Keiser, K., Nair, J. K., Charisse, K., Manoharan, R. M., Kretschmer, P., Peng, C. G., V. Kel’in, A., Kandasamy, P., Willoughby, J. L. S., et al. (2015) · ACS Chemical Biology · doi:10.1021/cb501028c · Cited by 221
Self-citationNielsen, P. E., Haaima, G., Lohse, A., & Buchardt, O. (1996) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199619391 · Cited by 221
RNA Hydration: A Detailed Look,
Egli, M., Portmann, S., & Usman, N. (1996) · Biochemistry · doi:10.1021/bi9607214 · Cited by 221
Self-citationAntisense Drug Technology: Principles, Strategies, and Applications
Szymkowski, D. E. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(01)02123-7 · Cited by 218
Dhillon, S. (2020) · Drugs · doi:10.1007/s40265-020-01339-3 · Cited by 218
EMILSSON, G. M., NAKAMURA, S., ROTH, A., & BREAKER, R. R. (2003) · RNA · doi:10.1261/rna.5680603 · Cited by 216
RNA structural motifs: building blocks of a modular biomolecule
Hendrix, D. K., Brenner, S. E., & Holbrook, S. R. (2005) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583506004215 · Cited by 216
Current Development of siRNA Bioconjugates: From Research to the Clinic
Chernikov, I. V., Vlassov, V. V., & Chernolovskaya, E. L. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00444 · Cited by 216
Minor groove RNA triplex in the crystal structure of a ribosomal frameshifting viral pseudoknot.
Rich, A., Su, L., Chen, L., Egli, M., & Berger, J. M. (1999) · Nature Structural Biology · doi:10.1038/6722 · Cited by 212
Self-citationOligonucleotide Synthesis on a Polymer Support1,2
Letsinger, R. L., & Mahadevan, V. (1965) · Journal of the American Chemical Society · doi:10.1021/ja01093a058 · Cited by 210
Volanesorsen: First Global Approval
Paik, J., & Duggan, S. (2019) · Drugs · doi:10.1007/s40265-019-01168-z · Cited by 208
Brautigam, C. A., & Steitz, T. A. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1586 · Cited by 205
Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo
Biscans, A., Coles, A., Haraszti, R., Echeverria, D., Hassler, M., Osborn, M., & Khvorova, A. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1239 · Cited by 205
Nucleoside conformation is determined by the electronegativity of the sugar substituent
Guschlbauer, W., & Jankowski, K. (1980) · Nucleic Acids Research · doi:10.1093/nar/8.6.1421 · Cited by 204
Henry, S. P., Giclas, P. C., Leeds, J., Pangburn, M., Auletta, C., Levin, A. A., & Kornbrust, D. J. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36667-4 · Cited by 204
Liebow, A., Li, X., Racie, T., Hettinger, J., Bettencourt, B. R., Najafian, N., Haslett, P., Fitzgerald, K., Holmes, R. P., Erbe, D., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030338 · Cited by 201
Antisense oligonucleotides: A primer
Scoles, D. R., Minikel, E. V., & Pulst, S. M. (2019) · Neurology Genetics · doi:10.1212/nxg.0000000000000323 · Cited by 200
Unexpected origins of the enhanced pairing affinity of 2′-fluoro-modified RNA
Pallan, P. S., Greene, E. M., Jicman, P. A., Pandey, R. K., Manoharan, M., Rozners, E., & Egli, M. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1270 · Cited by 199
Self-citationStructural Studies of LNA:RNA Duplexes by NMR: Conformations and Implications for RNase H Activity
Bondensgaard, K., Petersen, M. Å., Singh, S. K., Rajwanshi, V. K., Kumar, R., Wengel, J., & Jacobsen, J. P. (2000) · Chemistry - A European Journal · Cited by 196
Dna Methylation and its Possible Biological Roles
Razin, A., & Friedman, J. (1981) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(08)60482-1 · Cited by 194
Tapping the RNA world for therapeutics
Lieberman, J. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0054-4 · Cited by 194
Unique Gene‐Silencing and Structural Properties of 2′‐Fluoro‐Modified siRNAs
Manoharan, M., Akinc, A., Pandey, R. K., Qin, J., Hadwiger, P., John, M., Mills, K., Charisse, K., Maier, M. A., Nechev, L., et al. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201006519 · Cited by 193
Self-citationPrecise and efficient siRNA design: a key point in competent gene silencing
Fakhr, E., Zare, F., & Teimoori-Toolabi, L. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.4 · Cited by 191
Espeseth, A. S., Cejas, P. J., Citron, M. P., Wang, D., DiStefano, D. J., Callahan, C., Donnell, G. O., Galli, J. D., Swoyer, R., Touch, S., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-0163-z · Cited by 190
Development of the CpG Adjuvant 1018: A Case Study
Campbell, J. D. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-6445-1_2 · Cited by 189
Klettner, A., & Roider, J. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2055 · Cited by 187
Fomivirsen – a phosphorothioate oligonucleotide for the treatment of CMV retinitis
de Smet, M. D., Meenken, C., & van den Horn, G. J. (1999) · Ocular Immunology and Inflammation · doi:10.1076/ocii.7.3.189.4007 · Cited by 187
Rajeev, K. G., Nair, J. K., Jayaraman, M., Charisse, K., Taneja, N., O'Shea, J., Willoughby, J. L. S., Yucius, K., Nguyen, T., Shulga‐Morskaya, S., et al. (2015) · ChemBioChem · doi:10.1002/cbic.201500023 · Cited by 185
Self-citationMeier, M., Bider, M. D., Malashkevich, V. N., Spiess, M., & Burkhard, P. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3853 · Cited by 182
Cellular Uptake and Intracellular Trafficking of Antisense and siRNA Oligonucleotides
Juliano, R. L., Ming, X., & Nakagawa, O. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200377d · Cited by 181
Sequence-specific binding of counterions to B-DNA
Denisov, V. P., & Halle, B. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.629 · Cited by 181
Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition
(2007) · CRC Press eBooks · doi:10.1201/9780849387951 · Cited by 181
The Expanded Universe of Prokaryotic Argonaute Proteins
Ryazansky, S., Kulbachinskiy, A., & Aravin, A. A. (2018) · mBio · doi:10.1128/mbio.01935-18 · Cited by 180
Comparison of approaches for rational siRNA design leading to a new efficient and transparent method
Matveeva, O., Nechipurenko, Y., Rossi, L., Moore, B., Saetrom, P., Ogurtsov, A. Y., Atkins, J. F., & Shabalina, S. A. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm088 · Cited by 179
Hybrids of RNA and Arabinonucleic Acids (ANA and 2‘F-ANA) Are Substrates of Ribonuclease H
Damha, M. J., Wilds, C. J., Noronha, A., Brukner, I., Borkow, G., Arion, D., & Parniak, M. A. (1998) · Journal of the American Chemical Society · doi:10.1021/ja982325+ · Cited by 179
Crystal structure and improved antisense properties of 2'-O-(2-methoxyethyl)-RNA.
Manoharan, M., Egli, M., Teplova, M., Minasov, G., Tereshko, V. A., Inamati, G. B., & Cook, P. D. (1999) · Nature Structural Biology · doi:10.1038/9304 · Cited by 178
Self-citationRNA aptamers and their therapeutic and diagnostic applications.
Germer, K., Leonard, M., & Zhang, X. (2013) · Europe PMC (PubMed Central) · Cited by 174
Therapeutic Potential of Splice-Switching Oligonucleotides
Bauman, J. A., Jearawiriyapaisarn, N., & Kole, R. (2009) · Oligonucleotides · doi:10.1089/oli.2008.0161 · Cited by 174
Michelson, A. M., & Todd, A. R. (1955) · J. Chem. Soc. · doi:10.1039/jr9550002632 · Cited by 174
Stitching together RNA tertiary architectures
Hermann, T., & Patel, D. J. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3312 · Cited by 173
Beyond the seed: structural basis for supplementary microRNA targeting by human Argonaute2
Sheu‐Gruttadauria, J., Xiao, Y., Gebert, L. F. R., & MacRae, I. J. (2019) · The EMBO Journal · doi:10.15252/embj.2018101153 · Cited by 173
Cited by
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
RNAi-based drug design: considerations and future directions
Tang, Q., & Khvorova, A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00912-9 · Cited by 282
Lauffer, M. C., van Roon-Mom, W., Aartsma-Rus, A., & Collaborative, N. =. 1. (2024) · Communications Medicine · doi:10.1038/s43856-023-00419-1 · Cited by 273
Sorets, A. G., Schwensen, K. R., Francini, N., Kjar, A., Abdulrahman, A. M., Shostak, A., Katdare, K. A., Schoch, K. M., Cowell, R. P., Park, J. C., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf600 · Cited by 6
“The development of precise therapeutic modalities such as short interfering RNA (siRNA) has expanded the toolbox of medicines to correct disease-driving defects, as evidenced by the recent FDA approval of GalNAc conjugates that act in the liver [ 1 ].”
Sorets, A., Schwensen, K., Francini, N., Kjar, A., Abdulrahman, A., Shostak, A., Katdare, K., Schoch, K., Cowell, R., Park, J., et al. (2024) · doi:10.1101/2024.06.09.598079 · Cited by 4
Metadata
- Authors
- Egli, M., & Manoharan, M.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-03-07
- Volume
- 51
- Issue
- 6
- Pages
- 2529-2573
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W4323352404
- Cited by
- 828
- References
- 386
- FWCI
- 62.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.